Additionally, we analyzed prostate cancer expression data from men with clinical records of Gleason score and prostate-specific antigen (PSA) levels28, 30, 38, 40, the indicators of prostate cancer aggressiveness, finding that CCND2 mRNA levels were significantly lower in tumors with high Gleason score and elevated PSA levels (Fig. 3h–l and Supplementary Fig. 2k–m). This evidence concerns the gene CCND2 and prostate carcinoma.